Adherence to the MEDLIFE index reduced adverse cardiovascular events by 58% (HR=0.32) over 17 months in patients with ischemic heart disease and atrial fibrillation.
Does high adherence to the MEDLIFE index reduce adverse cardiovascular events in inpatients with ischemic heart disease and/or atrial fibrillation?
High adherence to a Mediterranean lifestyle, as measured by the MEDLIFE index, is associated with a significantly reduced risk of recurrent cardiovascular events in patients with established ischemic heart disease or atrial fibrillation.
Absolute Event Rate: 0% vs 0%
Abstract Introduction The MEDLIFE index is a validated tool for assessing adherence to a Mediterranean lifestyle, considering dietary habits, culinary preferences, physical activity, rest, and sociability. While previously associated with cardiometabolic outcomes in primary prevention, its role in secondary prevention of cardiovascular disease (CVD) remains unexplored. Purpose Our objective was to investigate the association between the MEDLIFE index and adverse events in patients with established CVD. Methods The pilot study recruited a prospective cohort of 115 inpatients admitted for ischemic heart disease (IHD) and/or atrial fibrillation (AF). Adherence to the MEDLIFE index (0-30 points) was assessed at baseline, and participants were categorized into sex-specific tertiles. Adverse events were defined as the incidence during follow-up of a composite outcome, including acute myocardial infarction, new revascularization, AF diagnosis or decompensation, stroke, and all-cause mortality. Results After a median follow-up of 17 months, 32 incident adverse events were identified. Participants in the highest category of adherence to the MEDLIFE index (18-24 points) had a 58% lower risk of adverse events compared to those with lower adherence (9-15 points) (adjusted HR=0.32; 95%CI: 0.12-0.84). Adherence to recommendations regarding reduced consumption of snacks and pastries and limiting between-meal snacking were independently associated with a reduction in adverse events. Conclusions Greater adherence to the MEDLIFE score was significantly associated with lower risk of adverse events in patients with IHD and AF. In future studies, the effectiveness of MEDLIFE-based interventions for cardiovascular prevention in routine clinical practice should be evaluated.
Díaz-Gutiérrez et al. (Sat,) reported a other. Adherence to the MEDLIFE index reduced adverse cardiovascular events by 58% (HR=0.32) over 17 months in patients with ischemic heart disease and atrial fibrillation.